XOMA’s (XOMA) Buy Rating Reiterated at HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $74.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 188.61% from the stock’s previous close.

XOMA Stock Performance

XOMA stock opened at $25.64 on Thursday. The business’s fifty day moving average is $24.69 and its 200-day moving average is $20.30. The company has a quick ratio of 8.68, a current ratio of 8.68 and a debt-to-equity ratio of 1.34. The company has a market cap of $298.45 million, a P/E ratio of -6.35 and a beta of 0.58. XOMA has a twelve month low of $13.48 and a twelve month high of $27.00.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.13). The business had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.01 million. XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. Equities research analysts forecast that XOMA will post -1.73 EPS for the current year.

Institutional Trading of XOMA

An institutional investor recently bought a new position in XOMA stock. Barclays PLC acquired a new position in shares of XOMA Co. (NASDAQ:XOMA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,468 shares of the biotechnology company’s stock, valued at approximately $28,000. Institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.